반응식
N[C:2]1[CH:7]=[CH:6][C:5]([N:8]2[CH2:14][CH2:13][CH2:12][N:11](C(OC(C)(C)C)=O)[CH2:10][CH2:9]2)=[CH:4][C:3]=1[NH:22][S:23]([C:26]1[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=1)(=[O:25])=[O:24].[N:32]1[O:33][N:34]=[C:35]2[C:40](S([Cl:44])(=O)=O)=[CH:39][CH:38]=[CH:37][C:36]=12>>[ClH:44].[N:32]1[O:33][N:34]=[C:35]2[C:40]([NH:22][S:23]([C:2]3[CH:7]=[CH:6][C:5]([N:8]4[CH2:14][CH2:13][CH2:12][NH:11][CH2:10][CH2:9]4)=[CH:4][C:3]=3[NH:22][S:23]([C:26]3[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=3)(=[O:25])=[O:24])(=[O:25])=[O:24])=[CH:39][CH:38]=[CH:37][C:36]=12참가 물질
3
실험 절차
N-(2,1,3-benzoxadiazol-4-yl)-4-(1,4-diazepan-1-yl)-2-[(phenylsulfonyl)amino]benzenesulfonamide hydrochloride was synthesized from N-{2-amino-5-(4-t-butyloxycarbonyl-1,4-diazepan-1-yl)-phenyl}benzenesulfonamide (0.072 g, 0.16 mmol) and 2,1,3-benzoxadiazol-4-yl sulfonyl chloride (0.072 g, 0.21 mmol) to give 38.0 mg of a light purple solid; M+1 537.2 Calcd 537.15; 1HNMR δ 8.21 (d, 1H), 7.80 (d, 1H), 7.68-7.46 (m, 6H), 6.92 (d, 1H), 6.49 (dd, 1H), 6.12 (d, 1H), 3.57 (app t, 2H), 3.34 (app t, 2H), 3.17 (app t, 2H), 3.11 (app t, 2H), 2.03-1.95 (m, 2H).
출처 및 근거
- ORD 기록
- ord-2cf800f8ac2a4aba949fd44b103adffd
- 출처 데이터셋
- uspto-grants-2005_11
- 특허 번호
- US06969710B2
연결된 노트
불러오는 중…